Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImageneBio, Inc.IKNA · Entity 7139 | Chief Scientific Officer | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImageneBio, Inc.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.62 · Expires 2033-01-03 | Direct | 105,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 105,000 · Balance 105,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 16:15 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0000899243-23-000987 · doc4.xml · derivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 18:14 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-22-004887 · doc4.xml · derivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionStock Option (Right to Buy) · Derivative | 964 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · derivative · entry 6 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,473 Underlying: Common Stock · 964 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 964 | $12.00 | $11,568.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 4 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionCommon Stock | 964 | $2.15 | $2,068.94 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 3 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · derivative · entry 5 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,437 Underlying: Common Stock · 36 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 36 | $12.00 | $432.00 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 2 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 19:25 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionCommon Stock | 36 | $2.15 | $77.26 |
DisclosureSEC source: 0000899243-22-001806 · doc4.xml · nonDerivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · derivative · entry 3 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,473 Underlying: Common Stock · 1,000 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC | ImageneBio, Inc. IKNA · Entity 7139 | SaleCommon Stock | 1,000 | $14.76 | $14,759.90 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · nonDerivative · entry 2 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,475 Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 20:48 UTC | ImageneBio, Inc. IKNA · Entity 7139 | Exercise / conversionCommon Stock | 1,000 | $2.15 | $2,146.20 |
DisclosureSEC source: 0000899243-21-048230 · doc4.xml · nonDerivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 21:01 UTC | ImageneBio, Inc. IKNA · Entity 7139 | GrantStock Option (Right to Buy) · Derivative | 176,699 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0000899243-21-045918 · doc4.xml · derivative · entry 1 Zhang Xiaoyan Michelle · CIK 0001895321 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,699 Underlying: Common Stock · 176,699 shares Expires 2031-11-21 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on November 22, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.